Seaport Therapeutics begins Phase 2a trial for anxiety and sleep disorder drug
Steady: 0 in the last 7 days
Updated oct 9
The latest in this situation
How it started
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Seaport Therapeutics began a Phase 2a clinical trial in Australia on October 7, 2026, dosing the first patient. The trial is evaluating GlyphAgoTM in adults suffering from generalized anxiety disorder and sleep disturbance. The six-week study is designed to establish proof-of-pharmacology regarding sleep effects, with topline data expected in early 2028.
From investegate.co.uk
Why it matters
GlyphAgoTM is a novel prodrug of agomelatine, a drug that has shown high efficacy and tolerability compared to standard treatments for generalized anxiety disorder in previous studies. The trial aims to advance the drug through the clinical pipeline.
From investegate.co.uk
How it developed
Newest first. Tap a step to see who reported it.- PureTech Health plc and Seaport Therapeutics presented clinical data in Munich.Sub-event
Seaport Therapeutics begins Phase 2a trial in Australia.1 source